Recently, one study showed that in the case of triple-negative breast cancer (TNBC), administration of LSD1 inhibitor increases CD8+ cytotoxic T cell trafficking towards tumor sites with increased chemokine expression including CCL5, CXCL9, and CXCL10, which are known to recruit CD8+ T cells to tumors (Table 1) [62,112]. The gene discussed is CD8A; the disease is triple-negative breast carcinoma.